Literature DB >> 11101351

Simulations of the estrogen receptor ligand-binding domain: affinity of natural ligands and xenoestrogens.

B C Oostenbrink1, J W Pitera, J H Meerman.   

Abstract

We have carried out molecular dynamics (MD) simulations and free energy calculations on the alpha-subtype of the human estrogen receptor ligand-binding domain (ERalpha LBD) complexed with a number of known agonists and putative xenoestrogens. Our dynamical simulations of ligand-receptor complexes underscore the highly structured nature of the complex and offer some interesting insights into the structure-activity relationship (SAR) for these ligands. With traditional thermodynamic integration (TI) calculations, we calculate relative binding free energies for three known agonists, in good agreement with experimental values. The sheer number of possible xenoestrogenic compounds makes an approach using traditional free energy calculations unfeasible. Instead, we have made use of a single-step perturbation methodology that allows the calculation of relative free energies for a large number of related polyaromatic hydrocarbons (PAHs) from a single simulation. Our results show good (maximum deviation 3.3 kJ mol(-1)) agreement with experimental data, suggesting the possibility of large-scale xenoestrogen screening in silico to obtain strongly estrogenic compounds for subsequent experimental testing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101351     DOI: 10.1021/jm001045d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

Review 1.  Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations.

Authors:  Julien Michel; Jonathan W Essex
Journal:  J Comput Aided Mol Des       Date:  2010-05-28       Impact factor: 3.686

2.  Structural modeling of high-affinity thyroid receptor-ligand complexes.

Authors:  Alexandre Suman de Araujo; Leandro Martínez; Ricardo de Paula Nicoluci; Munir S Skaf; Igor Polikarpov
Journal:  Eur Biophys J       Date:  2010-05-30       Impact factor: 1.733

3.  Computational estimation of rainbow trout estrogen receptor binding affinities for environmental estrogens.

Authors:  Conrad Shyu; Timothy D Cavileer; James J Nagler; F Marty Ytreberg
Journal:  Toxicol Appl Pharmacol       Date:  2010-11-12       Impact factor: 4.219

4.  Validation of the GROMOS force-field parameter set 45Alpha3 against nuclear magnetic resonance data of hen egg lysozyme.

Authors:  T A Soares; X Daura; C Oostenbrink; L J Smith; W F van Gunsteren
Journal:  J Biomol NMR       Date:  2004-12       Impact factor: 2.835

5.  Free energies of ligand binding for structurally diverse compounds.

Authors:  Chris Oostenbrink; Wilfred F van Gunsteren
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

6.  Validation of the 53A6 GROMOS force field.

Authors:  Chris Oostenbrink; Thereza A Soares; Nico F A van der Vegt; Wilfred F van Gunsteren
Journal:  Eur Biophys J       Date:  2005-04-01       Impact factor: 1.733

7.  In-silico screening using flexible ligand binding pockets: a molecular dynamics-based approach.

Authors:  Dakshanamurthy Sivanesan; Rajendram V Rajnarayanan; Jason Doherty; Nagarajan Pattabiraman
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

8.  Absolute FKBP binding affinities obtained via nonequilibrium unbinding simulations.

Authors:  F Marty Ytreberg
Journal:  J Chem Phys       Date:  2009-04-28       Impact factor: 3.488

9.  Estimation of relative binding free energy based on a free energy variational principle for the FKBP-ligand system.

Authors:  Takeshi Ashida; Takeshi Kikuchi
Journal:  J Comput Aided Mol Des       Date:  2013-06-11       Impact factor: 3.686

10.  Novel naphthalene-based inhibitors of Trypanosoma brucei RNA editing ligase 1.

Authors:  Jacob D Durrant; Laurence Hall; Robert V Swift; Melissa Landon; Achim Schnaufer; Rommie E Amaro
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.